Correction to: Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain

Benzer Materyaller

• Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain
  Yazar:: Hey, John A., ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer’s Disease
  Yazar:: Hey, John A., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression
  Yazar:: Tolar, Martin, ve diğerleri
  Baskı/Yayın Bilgisi: (2021)
• Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval
  Yazar:: Tolar, Martin, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• Elucidating the Aβ42 Anti-Aggregation Mechanism of Action of Tramiprosate in Alzheimer’s Disease: Integrating Molecular Analytical Methods, Pharmacokinetic and Clinical Data
  Yazar:: Kocis, Petr, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)